Intelligence · Clinical Development
Pipeline search results
Programs matching “non-small-cell-lung-cancer” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 211 pipeline programs matching "non-small-cell-lung-cancer" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
AK112 Injection
Summit Therapeutics
Non-Squamous Non-small Cell Lung Cancer
1 trial -
AMG 706
Takeda
Non-Small Cell Lung Cancer
1 trial -
Abemaciclib
Eli Lilly and Company
Non Small Cell Lung Cancer
1 trial -
Alectinib
Hoffmann-La Roche
Non-Small Cell Lung Cancer
1 trial -
Alectinib - Usual
Lxo Ireland Designated Activity Company
ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
1 trial -
Almonertinib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Non-small Cell Lung Cancer Metastatic
1 trial -
Avelumab
Serono Europe Limited
First Line Non-Small Cell Lung Cancer
1 trial -
Bevacizumab-Pfizer
Pfizer
Non-Small Cell Lung Cancer
1 trial -
Chemotherapy
International Peace Maternity and Child Health Hospital
Non Small Cell Lung Cancer
1 trial -
DLY201619
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Non-small Cell Lung Cancer Stage IIIA
1 trial -
Darbepoetin alfa
Amgen
Non-Small Cell Lung Cancer
1 trial -
Docetaxel
Sanofi Pasteur
Non-small Cell Lung Cancer
1 trial -
Durvalumab
AstraZeneca
Non-Small Cell Lung Cancer
2 trials -
Durvalumab
Arcus Biosciences
Non-Small Cell Lung Cancer
1 trial -
Durvalumab
AstraZeneca
Non Small Cell Lung Cancer NSCLC
1 trial -
EIK1001
Eikon Therapeutics
Non Small Cell Lung Cancer (Squamous or Non Squamous)
1 trial -
Firmonertinib
ArriVent BioPharma
Non-Small-Cell Lung Cancer
1 trial -
GO29431
Hoffmann-La Roche
Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer
1 trial -
Gefitinib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Non-small Cell Lung Cancer
1 trial -
Ivonescimab Injection
Summit Therapeutics
Non-Small Cell Lung Cancer
2 trials -
JDQ443
Novartis Pharmaceuticals
Non-Small Cell Lung Cancer
1 trial -
MEDI4736
AstraZeneca
Non-Small Cell Lung Cancer
1 trial -
MO29872
Hoffmann-La Roche
Non-Small Cell Lung Cancer
1 trial -
Necitumumab
Eli Lilly and Company
Non Small Cell Lung Cancer
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.